(Washington, DC) – Today, Mayor Muriel Bowser announced that she has named Ashan M. Benedict as the interim Chief of Police at the Metropolitan Police Department (MPD). Chief Benedict has served as the Executive Assistant Chief of Police at MPD since April …
Activity and Safety Profile Reinforces Potential of CBX-12 in Solid Tumors Four Objective Responses Observed in Breast and Ovarian Cancers with CBX-12 Dose-Limiting Toxicity Identified as Myelosuppression NEW HAVEN, Conn., May 25, 2023 (GLOBE NEWSWIRE) -- …
MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation MP0317 demonstrates a favorable safety profile across Q3W and Q1W regimens, including the highest dose tested, 10mg/kg (Q3W) Present …
Encouraging preliminary anti-tumor activity observed in a patient with PD-L1 negative advanced non-small cell lung cancer Favorable preliminary safety profile for XTX101 observed at the recommended Phase 2 dose of 150 mg once every six weeks WALTHAM, Mass …
TCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across multiple solid tumor indications Treatment was well tolerated with a manageable safety profile and …
CLN-619 demonstrated monotherapy activity across a range of tumor types, including in patients whose cancer had progressed on checkpoint inhibitor therapy Initial data indicate an acceptable safety profile of CLN-619 across all doses assessed Based on …
Beyond Dentistry Clearwater are formally introducing their state-of-the-art dental digital imaging toolset to the public. CLEARWATER, FLORIDA, UNITED STATES, May 25, 2023 /EINPresswire.com/ -- Beyond Dentistry Clearwater Brings Sophisticated Dental …
Positive clinical response as demonstrated in 8 out of 12 patients receiving EVX-01 in combination with a checkpoint inhibitor The study met primary endpoints for tolerability and safety COPENHAGEN, Denmark, May 25, 2023 (GLOBE NEWSWIRE) -- Evaxion …
Evaxion developed a genetic adjuvant technology that boosts the immune responses of viral, bacterial and cancer vaccines Preclinically validated for both DNA and mRNA vaccines, and ready for clinical testing Anticipated large market potential for DNA and …
SANTA CLARA, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NVIDIA will present at the following events for the financial community: BofA Securities 2023 Global Technology Conference Tuesday, June 6, 9:20 a.m. Pacific time Rosenblatt's 3rd Annual Technology …
New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Conference call and webcast scheduled on Sunday, June 4, 2023 at 6:00 p.m. CT BRISBANE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq …
As of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression, with five confirmed partial responses (PRs) and three durable stable disease (DSD) responses, two of which have …
Triplet of ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with metastatic BRAF V600E-mutated colorectal cancer (CRC) showed a 40% (2/5) response rate; continued evaluation of this combination will focus on EC-naïve patients …
Interim data being presented at ASCO 2023 Annual Meeting Demonstrated median progression-free survival (PFS) of 10.4 months Demonstrated 12-month overall survival (OS) rate of 87.1% A disease control rate (disease stabilization or tumor shrinkage) of 70.6% …
WEST JORDAN, Utah, May 25, 2023 (GLOBE NEWSWIRE) -- Sportsman's Warehouse Holdings, Inc. ("Sportsman's Warehouse" or the “Company”) (Nasdaq: SPWH) today announced that the Company has been invited to participate in Craig-Hallum’s 20th …
TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- Mitchell Cohen, Chief Executive Officer and President of Urbanfund Corp. (TSX-V: UFC) (“Urbanfund” or the “Company”), confirmed today that the Company has filed its financial statements for the three months ended …
• Data show tumor shrinkage and prolonged disease control in both monotherapy and in combination with pembrolizumab • Oral, once-daily cancer treatment well tolerated with a manageable safety profile • Data to be reported at the 2023 ASCO Annual Meeting …
WOBURN, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at …
-FLX475-treated patients exhibited significant changes in immune pathways likely to enhance an antitumor response -FLX475 modifies the tumor microenvironment (TME) to resemble those of responders to anti-PD(L)1 monotherapy -Data to be presented at the 2023 …
AFM24-101 phase 1/2 results in 10 patients from the non-small cell lung cancer (NSCLC) cohort demonstrated clinical activity and a well-managed safety profile in heavily pretreated patients with EGFR mutant NSCLC; updated interim analysis data of 15 …
03 days 11:55:32
